MONMOUTH JUNCTION, NJ--(Marketwired - Mar 6, 2014) - Insmed Incorporated (
Highlights of the fourth quarter of 2013 and subsequent two months include:
- Reported positive interim data from the two-year, open-label extension study of ARIKAYCE, or liposomal amikacin for inhalation, to treat Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients, which demonstrated long-term safety and durability of effect at 12 months;
- Entered into a contract manufacturing agreement with Therapure Biopharma Inc. for the manufacture of ARIKAYCE;
- Received Orphan Medical Product Designation in the European Union for ARIKAYCE to treat lung infections caused by NTM;
- Secured another European patent allowance, thereby strengthening the Company's intellectual property position;
- Appointed David W.J. McGirr to its Board of Directors. Mr. McGirr is the former Chief Financial Officer of Cubist Pharmaceuticals, Inc.; and
- Appointed Peggy Berry as Vice President of Regulatory Affairs. Ms. Berry has more than 25 years of experience in the pharmaceutical industry and began her career at the U.S. Food and Drug Administration. Ms. Berry has secured ten drug approvals during her career. She will be reporting to Will Lewis, President and Chief Executive Officer (CEO).
"2013 was a transformational year, one in which we laid the foundation to build Insmed into a leading biopharmaceutical company operating at the intersection of orphan, pulmonary and infectious diseases," stated Will Lewis, President and CEO of Insmed. "Most significantly, we advanced the ARIKAYCE clinical programs to treat NTM lung disease as well as Pseudomonas aeruginosa in CF patients. We also expanded our leadership team with talented executives in key regulatory and commercial roles. Our collective talents are focused on advancing the regulatory strategy and filings for ARIKAYCE for the treatment of NTM lung infections and CF patients with Pseudomonas."
"In the near term we plan to report top-line results from our phase 2 clinical trial of ARIKAYCE to treat NTM lung infections. Following the release of these data, we expect to have discussions with regulatory authorities in the U.S. and Europe regarding a path forward to filing for approval. In the interim, we have initiated a comprehensive education campaign to raise awareness of NTM and to increase accurate and early diagnosis," added Mr. Lewis. "It is our goal to be the leader in this globally uncontested orphan disease market."
Fourth Quarter Financial Results
For the fourth quarter of 2013, Insmed reported a net loss attributable to common stockholders of $16.2 million, or $0.41 per share, compared with a net loss attributable to common stockholders of $15.5 million, or $0.49 per share, for the fourth quarter of 2012.
Research and development expenses for the fourth quarter of 2013 were $9.6 million as compared to $12.2 million for the fourth quarter of 2012. Fourth quarter 2013 research development expenses were primarily comprised of costs for clinical trial activities associated with the Company's phase 2 trial in patients with NTM lung disease in the U.S. and Canada and two-year open-label extension study in CF patients with Pseudomonas aeruginosa lung infections in Europe and Canada, and costs related to manufacturing process improvements.
General and administrative expenses for the fourth quarter of 2013 increased to $6.0 million from $3.6 million for the fourth quarter of 2012. The increase was primarily due to an increase of $1.0 million of pre-commercial market research and related costs and a $1.2 million increase in compensation expense (including a $0.3 million increase in non-cash stock compensation expense).
Full Year Financial Results
For 2013 Insmed posted a net loss attributable to common stockholders of $56.1 million, or $1.60 per share, compared with a net loss attributable to common stockholders of $41.4 million, or $1.56 per share, for 2012. The greater loss is primarily due to an increase in both research and development expenses and general and administrative expenses.
Research and development expenses for 2013 increased to $44.3 million from $29.8 million for 2012. The increase was primarily due to the increased activities related to our phase 3 clinical study in CF patients and related two-year, open-label safety study in Europe and Canada, and our phase 2 NTM clinical study in the United States. We initiated the phase 3 CF study and phase 2 NTM study in the second quarter of 2012 and initiated the two-year CF extension study in October 2012.
General and administrative expenses for 2013 increased to $22.2 million from $12.7 million in 2012. The increase was due primarily to a $5.5 million increase in compensation expense (including an increase of $3.9 million in non-cash stock-based compensation expense), a $1.8 million increase in professional fees, including a $1.4 million increase in legal fees related to the investigation, accounting and reporting of excess equity awards and $2.9 million for consulting expenses, mainly for market research and other related costs. The 2012 results included $2.2 million in severance expenses related to the departure of several executives and employees.
Balance Sheet Highlights and Cash Guidance
As of December 31, 2013, Insmed had cash, cash equivalents and short-term investments of $113.9 million, compared with $92.9 million as of December 31, 2012. The increase was primarily due to $67.0 million of net proceeds from an underwritten public offering of common stock completed in July 2013. The Company utilized $46.7 million of cash to fund operations during 2013. Excluding the one-time $11.5 million cash payment the Company received from Premacure (now Shire) in May 2013, net cash used in operating activities for 2013 would have been $58.2 million. As of December 31, 2013, working capital was $99.7 million.
During 2014 the Company plans to continue to fund further clinical development of ARIKAYCE, invest in third-party manufacturing capacity, support efforts to obtain regulatory approvals, and prepare for commercialization. Insmed estimates that its cash requirements to fund operations for the first quarter of 2014 will be in the range of $15.0 million to $17.0 million. The Company expects to provide additional 2014 cash guidance when it releases first quarter 2014 financial results.
Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKAYCE®, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. . For more information, visit www.insmed.com.
This release contains forward-looking statements. Words, and variations of words, such as "intend," "expect," "will," "anticipate," "believe," "continue," "propose" and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of clinical trials and clinical data, the anticipated benefits of Insmed's products, the anticipated timing of regulatory submissions, and the ability to obtain required regulatory approvals, bring products to market and successfully commercialize products and Insmed's cash needs constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of European, Canadian, U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting the Company's product candidates, delays in product development or clinical trials or other studies, patent disputes and other intellectual property developments relating to the Company's product candidates, unexpected regulatory actions, delays or requests, the failure of clinical trials or other studies or results of clinical trials or other studies that do not meet expectations, the fact that subsequent analyses of clinical trial or study data may lead to different (including less favorable) interpretations of trial or study results or may identify important implications of a trial or study that are not reflected in Company's prior disclosures, and the fact that trial or study results or subsequent analyses may be subject to differing interpretations by regulatory agencies, the inability to successfully develop the Company's product candidates or receive necessary regulatory approvals, inability to make product candidates commercially successful, changes in anticipated expenses, changes in the Company's financing requirements or ability raise additional capital, and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent filings. Investors are cautioned not to place undue reliance on any forward-looking statements that speak only as of the date of this news release. The Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances or changes in its expectations.
-Tables to Follow-
|Consolidated Balance Sheets|
|(in thousands, except par value, share and per share data)|
|December 31, 2013||December 31, 2012|
|Cash and cash equivalents||$||113,894||$||90,782|
|Certificate of deposit||-||2,153|
|Prepaid expenses and other current assets||2,269||643|
|Total current assets||116,163||93,578|
|In-process research and development||58,200||58,200|
|Fixed assets, net||1,812||1,666|
|Liabilities and shareholders' equity|
|Accrued lease expense, current||307||295|
|Capital lease obligations, current||64||96|
|Current portion of long term debt||3,283||3,007|
|Total current liabilities||16,456||15,747|
|Accrued lease expense, long-term||380||647|
|Capital lease obligations, long-term||-||64|
|Common stock, $0.01 par value; 500,000,000 authorized shares, 39,137,679 and 31,488,204 issued and outstanding shares at December 31, 2013 and December 31, 2012, respectively||391||315|
|Additional paid-in capital||534,554||455,325|
|Warrant to purchase common stock||-||790|
|Total shareholders' equity||143,324||120,882|
|Total liabilities and shareholders' equity||$||176,498||$||153,561|
|Consolidated Income Statement|
|(in thousands, except per share data)|
|Three Months Ended December 31,||Twelve Months Ended December 31,|
|Research and development||9,625||12,228||44,279||29,781|
|General and administrative||5,969||3,605||22,236||12,657|
|Total operating expenses||15,594||15,833||66,515||42,438|
|Loss before income taxes||(16,214||)||(15,451||)||(57,294||)||(41,374||)|
|Provision (benefit) for income taxes||-||-||(1,221||)||-|
|Basic and diluted net loss per share||$||(0.41||)||$||(0.49||)||$||(1.60||)||$||(1.56||)|
|Weighted average basic and diluted common shares outstanding||39,116||31,373||34,980||26,545|
- Health Care Industry